Alzheimer’s Disease GWAS Summary Data (Kunkle)#
The SNP-level association testing summary statistics for Alzheimer’s disease from Kunkle et al 2019 Nature Genetics. Position values were converted from hg19 to hg38 using liftOver.
Contact#
Oluwatosin Olayinka
Path(s) to summary statistics#
- NIAGADS FTP,
/ftp_fgc_xqtl/projects/ADGWAS_Kunkle_2019_hg38_liftover/kunkle_sumstat_hg38_qc.chr* - CU
- original data (in GRCh37)
- stage 1:
/mnt/vast/hpc/csg/data_public/GWAS_sumstats/20231011_Kunkle/'Kunkle_etal_Stage1_results.txt?file=1' - stage 2:
/mnt/vast/hpc/csg/data_public/GWAS_sumstats/20231011_Kunkle/'Kunkle_etal_Stage2_results.txt?file=1'
- stage 1:
- liftover data (in GRCh38):
- stage 1:
/mnt/vast/hpc/csg/data_public/GWAS_sumstats/20231011_Kunkle/Kunkle_etal_Stage1_results.txt_file_1_hg38.txt - stage 2:
/mnt/vast/hpc/csg/data_public/GWAS_sumstats/20231011_Kunkle/Kunkle_etal_Stage2_results.txt_file_1_hg38.txt
- stage 1:
- original data (in GRCh37)
Path to SuSiE RSS Fine-mapping Objects#
- Li-San Wang FTP:
/ftp_fgc_xqtl/projects/GWAS_Finemapping_Results/Kunkle/
Download source#
This data is derived from summary statistics from the Kunkle et al. Nature Genetics paper.
File Schema#
chromosome: chromosome IDposition: hg38 position (converted from hg19 with liftOver)variant: variant ID in the formchr${chromosome}_${position}_${ref}_${alt}alt: alternative effect alleleref: reference allelebeta: SNP effect sizese: standard error ofbetapvalue: p-value ofbeta
Links to GWAS data analysis notebooks#
- Summary statistics preprocessing: https://github.com/floutt/brain-xqtl-analysis/blob/main/analysis/Zhang_BU/susie_rss/summary_stat_qc_all.nb.html
Cohorts included in this study#
46 case-control studies: 21,982 cases + 41,944 controls
final sample: 94,437 individuals = 35,274 clinical and autopsy-documented AD cases + 59,163 controls
4 consortia (46 case-control studies in Suppl. Table 2) non-Hispanic Whites (NHW):
ADGC: Alzheimer Disease Genetics Consortium
CHARGE: Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium
EADI: The European Alzheimer’s Disease Initiative
GERAD/PERADES: Genetic and Environmental Risk in AD/Defining Genetic, Polygenic and Environmental Risk for Alzheimer’s Disease Consortium"
Supplementary Table 1. Description of the consortium data sets used for Stage 1 discovery, Stage 2 and Stage 3. Discovery
| Alzheimer’s disease cases | Controls | |||||
|---|---|---|---|---|---|---|
| Consortium | N | Percent female | Mean AAO (s.d) | N | Percent female | Mean AAE (s.d) |
| ADGC | 14,428 | 59.3 | 71.1 (17.3) | 14,562 | 59.3 | 76.2 (9.9) |
| CHARGE | 2,137 | 67.3 | 82.6 (12) | 13,474 | 55.8 | 76.7 (8.2) |
| EADI | 2,240 | 65 | 75.4 (9.1) | 6,631 | 60.6 | 78.9 (7.0) |
| GERAD | 3,177 | 64 | 73.0 (0.2) | 7,277 | 51.8 | 51.0 (0.1) |
| N | 21,982 | 41,944 |
Stage 2*
| Country | N | Percent female | Mean AAO (s.d) | N | Percent female | Mean AAE (s.d.) |
|---|---|---|---|---|---|---|
| Belgium | 878 | 66.1 | 78.8 (8.2) | 661 | 59.5 | 65.7 (14.3) |
| Finland | 422 | 68 | 71.4 (6.9) | 562 | 59.3 | 69.1 (6.2) |
| Germany | 972 | 63.9 | 73.0 (8.6) | 2,378 | 53.1 | 69.5 (10.1) |
| Greece | 256 | 63.3 | 73.1 (7.9) | 229 | 34.1 | 49.3 (16.4) |
| Hungary | 125 | 68 | 78.9 (7.3) | 100 | 69 | 74.4 (6.5) |
| Italy | 1,729 | 66.5 | 71.5 (8.7) | 720 | 55.7 | 70.0 (10.4) |
| Spain | 2,121 | 66.3 | 75.0 (8.3) | 1,921 | 55.3 | 70.2 (10.8) |
| Sweden | 797 | 61.7 | 76.8 (8.1) | 1,506 | 62.8 | 70.6 (8.7) |
| UK | 490 | 67.6 | 74.6 (8.7) | 1,066 | 29.2 | 73.8 (6.5) |
| USA | 572 | 61.9 | 83.5 (7.6) | 1,340 | 54 | 79.3 (6.8) |
| N | 8,362 | 10,483 |
Stage 3*
| Country | N | Percent female | Mean AAO (s.d) | N | Percent female | Mean AAE (s.d.) |
|---|---|---|---|---|---|---|
| Spain (ACE) | 932 | 71 | 77.7 (7.9) | 1,813 | 68.4 | 54.7 (12.1) |
| UK (Cardiff) | 1,902 | 64.8 | 77.1 (7.9) | 1,047 | 57.8 | 73.9 (12.9) |
| USA (ADC7) | 514 | 51.3 | 73.9 (8.3) | 790 | 63.6 | 72.3 (7.7) |
| Spain (GR@ACE) | 1,582 | 74.6 | 78.5 (8.0) | 3,086 | 48 | 54.0 (14.0) |
| N | 4,930 | 6,736 |
- AAO, age at onset; AAE, age at examination.
- *Stage 2 and Stage 3 datasets were combined for genotyping of 33 replication variants not present on the 2013 custom chip
Supplementary Table 2. Demographic description of datasets within each consortium.
| Consortium | AD cases | Controls | |||||
|---|---|---|---|---|---|---|---|
| N | % female | Mean AA (SD) | N | % female | Mean AAE (SD) | ||
| ADGC | ACT | 532 | 62.6 | 78.8 (12.7) | 1,571 | 55.6 | 81.7 (5.9) |
| ADGC | ADC1 | 1,549 | 54.3 | 71.6 (11.0) | 512 | 59.2 | 76.8 (8.8) |
| ADGC | ADC2 | 727 | 50.8 | 61.4 (29.5) | 156 | 67.9 | 75.8 (7.9) |
| ADGC | ADC3 | 894 | 54.7 | 58.6 (32.8) | 586 | 63 | 72.8 (17.5) |
| ADGC | ADC4 | 304 | 55.3 | 73.4 (7.0) | 377 | 63.9 | 75.7 (8.1) |
| ADGC | ADC5 | 286 | 53.1 | 73.7 (7.0) | 505 | 65.5 | 77.6 (9.0) |
| ADGC | ADC6 | 213 | 58.2 | 73.9 (7.6) | 338 | 66.6 | 74.6 (9.0) |
| ADGC | ADNI | 268 | 42.2 | 75.3 (7.1) | 173 | 40.5 | 78.6 (5.5) |
| ADGC | BIOCARD | 6 | 33.3 | 73.8 (6.1) | 112 | 62.5 | 68.0 (5.5) |
| ADGC | CHAP | 27 | 63 | 84.8 (7.6) | 144 | 52.8 | 81.8 (6.6) |
| ADGC | EAS | 9 | 44.4 | 85.2 (4.9) | 141 | 41.1 | 84.4 (5.2) |
| ADGC | GenADA | 666 | 56.9 | 72.8 (13.5) | 712 | 63.9 | 74.2 (7.0) |
| ADGC | MAYO | 658 | 57.4 | 73.6 (4.8) | 1,046 | 51.1 | 72.9 (4.4) |
| ADGC | MIRAGE | 491 | 63.3 | 69.9 (11.5) | 738 | 58.8 | 70.8 (12.1) |
| ADGC | MTC | 256 | 57 | 73.6 (11.8) | 189 | 61.4 | 70.9 (9.7) |
| ADGC | NIALOAD | 1,798 | 65 | 73.1 (9.3) | 1,568 | 60.2 | 73.8 (9.3) |
| ADGC | NBB | 80 | 71.3 | 74.5 (7.5) | 48 | 56.3 | 81.5 (9.4) |
| ADGC | OHSU | 132 | 62.1 | 85.9 (5.7) | 153 | 54.9 | 83.9 (7.6) |
| ADGC | PFIZER | 696 | 53.7 | 73.7 (5.0) | 762 | 54.1 | 77.2 (4.9) |
| ADGC | RMAYO | 13 | 23.1 | 78.5 (9.0) | 233 | 41.6 | 79.2 (5.8) |
| ADGC | ROSMAP | 295 | 70.5 | 85.6 (6.2) | 769 | 72 | 82.2 (7.1) |
| ADGC | ROSMAP2 | 59 | 78 | 81.9 (6.9) | 217 | 76 | 80.8 (7.2) |
| ADGC | TARC1 | 323 | 61.6 | 74.0 (7.1) | 181 | 65.2 | 73.9 (8.2) |
| ADGC | TGEN2 | 668 | 64.8 | 67.2 (22.9) | 365 | 48.5 | 80.0 (8.7) |
| ADGC | UKS | 596 | 57.4 | 72.2 (6.6) | 170 | 51.2 | 64.1 (3.0) |
| ADGC | UMCWRMSSM | 1,177 | 64.5 | 71.1 (17.4) | 1,126 | 61.3 | 73.5 (10.6) |
| ADGC | UPITT | 1,255 | 62.9 | 66.8 (22.4) | 829 | 63.3 | 75.5 (6.0) |
| ADGC | WASHU | 339 | 57.2 | 69.1 (21.5) | 187 | 60.4 | 76.9 (8.4) |
| ADGC | WASHU2 | 38 | 57.9 | 73.4 (7.3) | 94 | 46.8 | 51.7 (35.2) |
| ADGC | WHICAP | 73 | 72.6 | 83.9 (7.8) | 560 | 60.4 | 81.7 (6.7) |
| CHARGE | AGES | 95 | 51.6 | 81.5 (0.1) | 2,708 | 59.2 | 75.7 (0.1) |
| CHARGE | ASPS | 277 | 57.8 | 76.4 (8.3) | 169 | 58 | 66.4 (10.8) |
| CHARGE | CHS | 450 | 66 | 81.9 (5.2) | 1,702 | 60.3 | 81.1 (5.2) |
| CHARGE | FHS | 330 | 64 | 86.1 (7.2) | 3,910 | 49 | 74.0 (9.5) |
| CHARGE | ROTTERDAM | 985 | 73.2 | 83.5 (6.6) | 4,985 | 57.6 | 78.0 (7.6) |
| EADI | 2,240 | 65 | 75.4 (9.1) | 6,631 | 60.6 | 78.9 (7.0) | |
| GERAD | MRC | 1,008 | 70.3 | 80.9 (6.5) | 873 | 61.6 | 75.9 (6.3) |
| GERAD | ARUK | 939 | 61 | 76.6 (9.6) | 82 | 59.8 | 77.9 (7.6) |
| GERAD | BONN | 551 | 63.7 | 72.9 (8.3) | 37 | 64.9 | 79.5 (3.6) |
| GERAD | WASHU | 423 | 56 | 82.1 (9.0) | 156 | 65.4 | 78.5 (9.7) |
| GERAD | NIMH | 127 | 63 | 80.1 (6.1) | - | - | - |
| GERAD | UCL:PRION | 82 | 59.8 | 63.6 (9.9) | - | - | - |
| GERAD | UCL:LASER | 47 | 74.5 | 80.6(7.9) | - | - | - |
| GERAD | 1958BC | - | - | - | 5,342 | 49.8 | 45.0 (0.0) |
| GERAD | KORA | - | - | - | 434 | 49.1 | 56.0 (7.2) |
| GERAD | HNR | - | - | - | 353 | 52.9 | 54.6 (5.3) |
| GERAD | MAYO1 | - | - | - | - | - | - |
| TOTALS | 21,982 | 41,944 |